Chemotherapy-Associated Thrombotic Microangiopathy
Aklilu A, Shirali A. Chemotherapy-Associated Thrombotic Microangiopathy. Kidney360 2023, 4: 409-422. PMID: 36706238, PMCID: PMC10103319, DOI: 10.34067/kid.0000000000000061.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsMeSH KeywordsAntineoplastic AgentsGemcitabineHumansNeoplasmsProteasome InhibitorsThrombotic MicroangiopathiesConceptsDrug-induced thrombotic microangiopathyThrombotic microangiopathyPlasma exchangePrimary atypical hemolytic uremic syndromeAtypical hemolytic uremic syndromeEnd-organ dysfunctionMicroangiopathic hemolytic anemiaSecondary thrombotic microangiopathyTherapeutic plasma exchangeTerminal complement inhibitorLarge multicenter studyHemolytic uremic syndromeRole of complementPotential treatment strategyProteinuria reductionSupportive careBlood pressureMulticenter studyTreatment courseUremic syndromeComplement inhibitionTreatment strategiesHemolytic anemiaAntiangiogenesis agentsComplement inhibitors
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply